A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2030

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Targeted drugs combined with anti-PD-1/PD-L1 antibodies

Targeted drugs combined with anti-PD-1/PD-L1 antibodies

DRUG

TACE (transarterial chemoembolization) combined with targeted/immunotherapy

TACE (transarterial chemoembolization) combined with targeted/immunotherapy

DRUG

Lenvatinib monotherapy

For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.

DRUG

Huaier granules combined with any of the above Cohorts for treatment

Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.

All Listed Sponsors
collaborator

LinkDoc Technology (Beijing) Co. Ltd.

INDUSTRY

collaborator

Huazhong University of Science and Technology

OTHER

lead

Fudan University

OTHER

NCT05660213 - A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer | Biotech Hunter | Biotech Hunter